This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Markets Flip Higher Late Session; Q1 Reports from CAR, NXPI & More
by Mark Vickery
Avis Budget, NXP Semi, Clorox and MGM all outperformed expectations after the closing bell today.
Clorox (CLX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 35.05% and 0.04%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Markets Wait for FOMC Meeting and Major Earnings This Week
by Zacks Equity Research
Markets Wait for FOMC Meeting and Major Earnings This Week
Market Indices Look to Break Long Losing Streaks
by Mark Vickery
It's been five weeks of losses for the Dow and four for the S&P 500 and Nasdaq.
Clorox (CLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Elevated manufacturing and logistics costs might have hurt Clorox's (CLX) bottom line in third-quarter fiscal 2022. Nonetheless, its IGNITE strategy appears encouraging.
Colgate-Palmolive (CL) Q1 Earnings Meet Estimates
by Zacks Equity Research
Colgate-Palmolive (CL) delivered earnings and revenue surprises of 0% and 0.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Clorox (CLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TechTarget and Clorox have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
TechTarget and Clorox have been highlighted as Zacks Bull and Bear of the Day.
Bear Of The Day: The Clorox Company (CLX)
by Daniel Laboe
Clorox's hoarding-fueled consumption behavior was proven to be unsustainable, with year-over-year top and bottom-line declines in its past 4 quarterly reports
ACM Research as the Bull of the Day and Clorox have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
ACM Research as the Bull of the Day and Clorox have been highlighted as Zacks Bull and Bear of the Day
Bear Of The Day: Clorox (CLX)
by Daniel Laboe
I recommend staying away from CLX until it can generate proven margin-improving results
Clorox (CLX) Dips as Q2 Earnings Lag Estimates, Lowers View
by Zacks Equity Research
Clorox (CLX) Q2 results hurt by soft sales performance across all segments, led by lower shipment volumes. Higher costs also hurt the bottom line.
Clorox (CLX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of -15.38% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Church & Dwight (CHD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Church & Dwight (CHD) delivered earnings and revenue surprises of 10.34% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Clorox (CLX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clorox (CLX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Clorox (CLX) Q2 results are likely to reflect impacts of unfavorable price mix, lower shipments, and elevated logistics and commodity costs. Its IGNITE strategy and productivity initiatives bode well.
4 Soaps & Cleaning Materials Stocks to Watch Amid Cost Woes
by Rajani Lohia
Elevated logistics, input and manufacturing costs have been eroding margins for several soap and cleaning materials companies amid aggravated supply-chain woes. Players like Procter & Gamble (PG), Colgate (CL), Church & Dwight (CHD) and Clorox (CLX) are expected to benefit from innovation.
Clorox (CLX) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Church & Dwight (CHD) Inks Deal to Acquire TheraBreath Brand
by Zacks Equity Research
Church & Dwight (CHD) inks an agreement to acquire leading mouthwash brand, TheraBreath. The deal, valued at $580 million, is expected to close in fourth-quarter 2021.
Company News for Nov 3, 2021
by Zacks Equity Research
Companies In The News Are: CLX, UAA, CMI, ZBRA.
Clorox (CLX) Q1 Earnings and Sales Top Estimates, Decline Y/Y
by Zacks Equity Research
Clorox (CLX) Q1 results gain from strength across the portfolio and robust demand. Lower volume and unfavorable price mix have been headwinds.
New All-Time Closing Highs for Dow, Nasdaq, S&P
by Mark Vickery
Market indexes were once again higher across the board this Monday, with three of the four majors reaching fresh all-time closing highs.
Clorox (CLX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 19.80% and 6.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Factors Likely to Influence Clorox (CLX) in Q1 Earnings
by Zacks Equity Research
Elevated manufacturing and logistics costs are expected to have hurt Clorox's (CLX) Q1 bottom line. Yet, its IGNITE strategy and cost-saving initiatives are likely to have been encouraging.
Analysts Estimate Clorox (CLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.